Ardelyx delivered a strong performance in Q4 2025, driven by significant growth in IBSRELA revenue and increased adoption of XPHOZAH. The company also advanced its clinical development programs, including a Phase 3 trial for IBSRELA in CIC and a new NHE3 inhibitor program, while maintaining a solid cash position.

Ardelyx delivered strong third-quarter results, with total revenue reaching $110.3 million, driven primarily by a 92% year-over-year increase in IBSRELA revenue to $78.2 million. XPHOZAH also showed consistent growth, contributing $27.4 million. The company reported a net loss of $1.0 million and announced a new pipeline program for RDX10531, a next-generation NHE3 inhibitor.

Ardelyx delivered an outstanding second quarter in 2025, generating $97.7 million in total revenue, a 33% increase year-over-year. Both commercial products, IBSRELA and XPHOZAH, showed significant results, with IBSRELA recording its highest revenue quarter at $65.0 million and XPHOZAH generating $25.0 million. The company ended the quarter with $238.5 million in cash, cash equivalents, and investments, and raised its 2025 IBSRELA net sales revenue expectations.

Ardelyx delivered an outstanding first quarter in 2025, with total revenue reaching $74.1 million, a 61% increase year-over-year. This growth was primarily fueled by strong sales of IBSRELA and XPHOZAH, demonstrating the company's commercial strategy and market momentum.

Ardelyx enters 2025 in a position of strength, evidenced by significant year-over-year revenue growth for IBSRELA in 2024 and a strong first full year of XPHOZAH commercialization.

Ardelyx reported a net loss of $0.8 million for Q3 2024, with total revenue of $98.2 million, driven by strong product sales of IBSRELA and XPHOZAH. The company ended the quarter with approximately $190.4 million in cash, cash equivalents, and investments.

Ardelyx reported a total revenue of $73.2 million for the second quarter of 2024, driven by net product sales of IBSRELA and XPHOZAH. The company ended the quarter with approximately $186 million in cash and investments. Net loss for the quarter was $16.5 million, or $(0.07) per share.

Ardelyx reported a strong first quarter in 2024, driven by increased net product sales and product supply revenue. The company saw substantial topline growth due to the continued commercial performance of IBSRELA and the strong launch of XPHOZAH. They thoughtfully managed expenses and ended the quarter with a strong cash position.

Ardelyx reported strong Q4 2023 financial results, driven by the commercial performance of IBSRELA and the launch of XPHOZAH. The company finished the year with $184.3 million in cash and investments and anticipates continued growth in 2024.

Ardelyx reported a net income of $6.6 million for Q3 2023, a significant improvement compared to the net loss of $22.9 million in Q3 2022. The company's total revenue increased to $56.4 million, driven by strong IBSRELA sales and licensing revenue. They also received FDA approval for XPHOZAH and initiated its commercial launch.

Ardelyx reported a successful Q2 2023 with IBSRELA net sales revenue of $18.3 million, representing a 61% quarter-over-quarter growth. The company anticipates IBSRELA net sales revenue to be between $72 and $77 million for the full year 2023. They are also preparing for the potential approval and launch of XPHOZAH in Q4, with a user fee goal date of October 17, 2023. The company ended Q2 with $127.6 million in cash and investments.

Ardelyx reported Q1 2023 financial results, highlighting the continued successful launch of IBSRELA with $11.4 million in net product sales. The company ended the quarter with over $130 million in cash and investments and resubmitted the XPHOZAH New Drug Application on April 17, 2023.

Ardelyx reported Q4 net product sales for IBSRELA of $8.7 million and ended the quarter with $123.9 million in cash and investments. The company is preparing for NDA resubmission for XPHOZAH in early Q2 2023.

Ardelyx reported a net product sales for IBSRELA were $4.9 million, collaboration revenue of $0.1 million, R&D expenses of $7.5 million, SG&A expenses of $18.7 million and net loss of $22.9 million for the quarter ended September 30, 2022.

Ardelyx reported a net product sales for IBSRELA of $1.6 million, collaboration revenue of $1.0 million, research and development expenses of $9.7 million, selling, general and administrative expenses of $18.9 million, and a net loss of $26.9 million for the second quarter ended June 30, 2022.

Ardelyx reported its first commercial product sales of IBSRELA with $0.5 million in revenue. The company is pursuing FDA approval for XPHOZAH and received notification from the FDA that an advisory committee meeting will be convened. Net loss for the quarter was $28.1 million, or $0.21 per share.

Ardelyx reported a net loss of $36.23 million for the fourth quarter of 2021. The company is preparing for the April 2022 launch of IBSRELA and anticipates becoming a revenue-generating company.

Ardelyx reported $1.2 million in revenue for Q3 2021, primarily from collaborative development with Kyowa Kirin. R&D expenses increased to $23.7 million, and G&A expenses rose to $19.7 million due to commercial infrastructure build-up. The company's net loss for the quarter was $43.6 million, and they had $141.7 million in cash, cash equivalents, and short-term investments as of September 30, 2021.

Ardelyx reported $1.3 million in revenue for Q2 2021, primarily from collaborative development with Kyowa Kirin. R&D expenses increased due to clinical study costs, while G&A expenses rose due to commercial infrastructure investments. The company's net loss was $45.2 million, compared to $25.0 million in the same quarter of the prior year. Ardelyx had $171.8 million in cash, cash equivalents, and short-term investments as of June 30, 2021.

Ardelyx reported first quarter revenue of $6.6 million, primarily from a milestone payment. Research and development expenses increased to $20.5 million, and general and administrative expenses rose to $17.1 million. The net loss for the quarter was $33.2 million.

Ardelyx reported total revenues of $1.809 million for the fourth quarter of 2020 and a net loss of $28.876 million. The company's cash, cash equivalents and investments are expected to fund operations into the second half of 2022.

Ardelyx reported Q3 2020 financial results, with the FDA accepting the NDA for tenapanor and a PDUFA goal date set for April 29, 2021. The company maintains a strong balance sheet with $185.5 million in cash, cash equivalents and short-term investments.

Ardelyx reported $1.8 million in revenue for Q2 2020, primarily from collaborative development. The company submitted a New Drug Application to the FDA for tenapanor and maintained a strong balance sheet with $204.8 million in cash, cash equivalents, and short-term investments.

Ardelyx reported $1.2 million in revenue for the quarter ended March 31, 2020. The company's cash, cash equivalents, and short-term investments totaled $223.2 million as of March 31, 2020. Net loss for the quarter was $22.4 million.

Ardelyx reported total revenues of $2.25 million for the fourth quarter of 2019 and a net loss of $19.79 million. The company's cash, cash equivalents, and short-term investments are expected to fund operations until early 2022.